1. Home
  2. ACTU
  3. ACTU News

Latest ACTUATE THERAPEUTICS INC (ACTU) News on June 1, 2025

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
ACTU

GlobeNewswire

9 days ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
ACTU

GlobeNewswire

25 days ago

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
ACTU

GlobeNewswire

a month ago

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
ACTU

GlobeNewswire

a month ago

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
ACTU

GlobeNewswire

a month ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
ACTU

GlobeNewswire

a month ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

ACTU

MT Newswires

2 months ago

Top Premarket Gainers

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
ACTU

GlobeNewswire

3 months ago

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?
ACTU

Simply Wall St.

4 months ago

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
ACTU

GlobeNewswire

4 months ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
ACTU

GlobeNewswire

5 months ago

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
ACTU

GlobeNewswire

5 months ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics to be Added to Russell 2000® Index
ACTU

GlobeNewswire

6 months ago

Actuate Therapeutics to be Added to Russell 2000® Index

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
ACTU

GlobeNewswire

7 months ago

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
ACTU

GlobeNewswire

7 months ago

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
ACTU

GlobeNewswire

8 months ago

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
ACTU

GlobeNewswire

9 months ago

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
ACTU

GlobeNewswire

9 months ago

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
ACTU

GlobeNewswire

9 months ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ACTU

GlobeNewswire

9 months ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
ACTU

GlobeNewswire

9 months ago

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

Actuate Therapeutics Announces Closing of Initial Public Offering
ACTU

GlobeNewswire

10 months ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Share on Social Networks: